The research of oral medications that enhance insulin resistance or sublingual treatment with insulin to restore brain insulin signaling for the management of Alzheimer's disease (AD) is now being implemented [74]. The gene discussed is INS; the disease is early-onset autosomal dominant Alzheimer disease.